Biomarkers for Oncology
JH · Effective Oct 1, 2015
30 active Medicare policies list 81301, and 4 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
J9 · Effective Jul 17, 2023
JH · Effective Jul 17, 2023
JL · Effective Jul 17, 2023
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
4 policies from 3 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of 81301 |
|---|---|---|
| Pharmacogenetic and Pharmacodynamic Testing | Feb 27, 2024 | Covered |
| Tumor Markers | Mar 5, 2024 | Covered |
| Policy | Effective | Status of 81301 |
|---|---|---|
| Concert Genetic Testing Oncology: Solid Tumor Molecular Diagnostics | Not recorded | Referenced |
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
J9 · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
JL · Effective Apr 24, 2025
National · Effective Jan 1, 2024
National · Effective Feb 19, 2026
National · Effective Jul 1, 2026
National · Effective Jul 1, 2026
National · Effective Jul 1, 2026
J5 · Effective Jul 1, 2026
JL · Effective Jul 1, 2026
J9 · Effective Jul 1, 2026
J6 · Effective Jul 15, 2026
J9 · Effective Jan 1, 2024
| Policy |
|---|
| Effective |
|---|
| Status of 81301 |
|---|
| Genetic Testing for Lynch Syndrome and APC-associated and MUTYH-associated Polyposis Syndromes | Feb 1, 2026 | Covered |
|---|